Vision & Strategy

 

Our Vision

Our vision is to grow Consort Medical into the leading customer-centric CDMO that delivers exceptional value to the supply chain from early stage drug and device development to full commercialisation.

Our Strategy

Optimising drug and device services in a single group will streamline and accelerate the route of drugs to market and reduce the cost and complexity of drug/device development for the Group’s pharmaceutical partners. We believe that such an offering is highly differentiated from Consort Medical’s current competitors.

Our Strategy for Sustainable Growth

The Group defines its Strategy for Sustainable Growth in four key elements:

  1. Sustainable Organic Revenue Growth

    • Market leading technologies and products
    • Highest levels of technical and regulatory expertise
    • Deep, long-term customer relationships & contracts
    • Broad range of programs and capabilities
  2. Margin improvement

    • High margin drug delivery device business
    • Delivering continued margin improvement in Aesica
    • Good operational leverage
  3. Investing in innovation

    • Well established development programmes in both divisions
    • Developing our own product innovations while committed to investing in new patient, clinician and customer-driven treatments
    • Differentiated “one-stop” capability
  4. Selective M&A and investments

    • Track record of successful acquisitions and integration
    • Strategy to access new geographic markets & complementary technologies
    • Clear criteria to generate sustainable long-term shareholder value